MEK and PI3K inhibition in solid tumors: rationale and evidence to date
E Jokinen, JP Koivunen - Therapeutic advances in medical …, 2015 - journals.sagepub.com
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic
pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to …
pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to …
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
CD Britten - Cancer chemotherapy and pharmacology, 2013 - Springer
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Q Li, Z Li, T Luo, H Shi - Molecular biomedicine, 2022 - Springer
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
E Jokinen, N Laurila, JP Koivunen - BMC cancer, 2012 - Springer
Abstract Background PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be
the central transducers of oncogenic signals in solid malignancies, and there has been a lot …
the central transducers of oncogenic signals in solid malignancies, and there has been a lot …
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
A De Luca, MR Maiello, A D'Alessio… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: The RAS/RAF/MAP kinase–ERK kinase (MEK)/extracellular-signal-regulated
kinase (ERK)(MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR)(PI3K) …
kinase (ERK)(MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR)(PI3K) …
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
T Shimizu, AW Tolcher, KP Papadopoulos… - Clinical Cancer …, 2012 - AACR
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving
PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated …
PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated …
Targeting the PI3K signaling pathway in cancer
KK Wong, JA Engelman, LC Cantley - Current opinion in genetics & …, 2010 - Elsevier
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human
cancers, and inhibitors of this pathway are under active development as anti-cancer …
cancers, and inhibitors of this pathway are under active development as anti-cancer …
Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors
AW Tolcher, W Peng, E Calvo - Molecular cancer therapeutics, 2018 - AACR
Molecular characterization of oncogenic mutations within genes in the MAPK and
PI3K/AKT/mTOR pathways has led to the rational development of targeted therapies …
PI3K/AKT/mTOR pathways has led to the rational development of targeted therapies …
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
Targeting the PI3K pathway in cancer: are we making headway?
F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …
pathways in cancer and, consequently, more than 40 compounds that target key …